“Unlocking Emcure Pharmaceuticals IPO”

2023 11 20 125201895 Emcure Pharma hires corporate finance advisors for IPO spot

Emcure Pharmaceuticals attracted significant investor interest, securing Rs 583 crore from anchor investors on July 2, a day prior to the IPO’s official opening. The book-running lead managers for the issue are Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India.

The equity shares of Emcure Pharmaceuticals are slated to debut on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on July 10.

Brokerages such as Anand Rathi, Canara Bank Securities, SBI Securities, and Mehta Equities have recommended subscribing to Emcure Pharmaceuticals IPO for the long term. Their positive outlook underscores the company’s potential and growth prospects within the pharmaceutical sector.

Investors keen on participating in the IPO are advised to consider these expert opinions alongside their own financial goals and risk tolerance.

Stay updated with the latest developments and analysis on Emcure Pharmaceuticals’ IPO as the market eagerly awaits its listing.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post
Tesla 990x707 1

Tesla Exceeds Expectations with Strong Car Sales Recovery

Next Post

Google Engineer Unveils World’s First AI Dress Named ” Robotic Medusa Dress “

Related Posts